We are live on ! Find out more
BHVN icon

Biohaven Pharmaceutical Holding Company Ltd.
BHVN

Delisted

BHVN was delisted on the 3rd of October, 2022.

Back to rankings

1 hedge funds and large institutions have $35M invested in Biohaven Pharmaceutical Holding Company Ltd. in 2026 Q2 according to their latest regulatory filings, with funds opening new positions, 1 increasing their positions, reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 1 → 1 (0)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

Holders
1
Holders Change
–
Holders Change %
0%
% of All Funds
0.01%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.01%
New
–
Increased
1
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
KCM
Knoll Capital Management
Florida
+$356K

Top Sellers

No sellers this quarter

BHVN Hedge Fund Activity: Q2 2026 in Review

1 of the 8,354 institutional investors tracked by Wall St. Rank reported a position in Biohaven Pharmaceutical Holding Company Ltd. (BHVN) for Q2 2026, worth a combined $35M — up 78% from $19.7M a quarter earlier.

Fund positioning in BHVN was balanced in Q2 2026: 0 funds opened new positions, 0 closed out, 1 added to existing stakes and 0 trimmed.

The largest buyer was Knoll Capital Management, adding an estimated $356K.

  • 1 institutional investor held Biohaven Pharmaceutical Holding Company Ltd. (BHVN) as of Q2 2026, unchanged from Q1 2026.
  • Funds reported $35M of Biohaven Pharmaceutical Holding Company Ltd. stock for Q2 2026, up 78% quarter-over-quarter.
  • 0 funds opened new Biohaven Pharmaceutical Holding Company Ltd. positions in Q2 2026 and 0 closed out.
  • The largest Biohaven Pharmaceutical Holding Company Ltd. buyer in Q2 2026 was Knoll Capital Management, an estimated $356K added.

Based on aggregated 13F filings for Q2 2026.